{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:42:14Z","timestamp":1777858934569,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lafrancol","award":["002"],"award-info":[{"award-number":["002"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Prim Care Community Health"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ischemic heart disease is the leading cause of death in the world and is associated with dyslipidemia, high blood pressure, diabetes mellitus, and other factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the clinical effectiveness on the lipid profile of the rosuvastatin\u2009+\u2009fenofibric acid combination in Colombian patients with high cardiovascular risk and mixed dyslipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Longitudinal observational study in a random sample of patients with a diagnosis of mixed dyslipidemia and moderate, high, or very high cardiovascular risk who were treated with rosuvastatin\u2009+\u2009fenofibric acid. Anthropometric, clinical, laboratory, comorbidity, and pharmacological variables were identified. Effectiveness on the lipid profile was determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 386 patients were analyzed. They had a mean age of 60.8\u2009\u00b1\u200911.4\u2009years, 53.1% were female, and 75.6% had high\/very high cardiovascular risk. The initial evaluation showed a mean LDL cholesterol of 138.4\u2009\u00b1\u200967.1\u2009mg\/dL and triglycerides of 679.7\u2009\u00b1\u2009573.6\u2009mg\/dL. At the end of follow-up, mean LDL cholesterol was 87.5\u2009\u00b1\u200941.2\u2009mg\/dL (reduced by 43.3%; P\u2009&lt;\u2009.001), and triglycerides were 243.5\u2009\u00b1\u2009170.5\u2009mg\/dL (reduced by 64.2%; P\u2009&lt;\u2009.001). Only 35.4% (n\u2009=\u200973) of patients with very high risk reached the goal of metabolic control, compared to 61.6% (n\u2009=\u200953) with high risk and 55.4% (n\u2009=\u200946) with moderate risk. Belonging to the very high-risk group was associated with a lower probability of achieving the control goal (OR: 0.32; 95%CI: 0.192-0.539).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of rosuvastatin\u2009+\u2009fenofibric acid is an effective option in patients with mixed dyslipidemia and high cardiovascular risk, providing a therapeutic alternative for those conditions that require it.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2150132720977733","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T08:05:42Z","timestamp":1606723542000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia"],"prefix":"10.1177","volume":"11","author":[{"given":"Manuel E.","family":"Machado-Duque","sequence":"first","affiliation":[{"name":"Universidad Tecnol\u00f3gica de Pereira-Audifarma S.A., Pereira, Colombia"},{"name":"Grupo Biomedicina, Fundaci\u00f3n Universitaria Aut\u00f3noma de las Am\u00e9ricas, Pereira, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Gaviria-Mendoza","sequence":"additional","affiliation":[{"name":"Universidad Tecnol\u00f3gica de Pereira-Audifarma S.A., Pereira, Colombia"},{"name":"Grupo Biomedicina, Fundaci\u00f3n Universitaria Aut\u00f3noma de las Am\u00e9ricas, Pereira, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"Jorge E.","family":"Machado-Alba","sequence":"additional","affiliation":[{"name":"Universidad Tecnol\u00f3gica de Pereira-Audifarma S.A., Pereira, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"bibr1-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8651(03)00080-8"},{"key":"bibr2-2150132720977733","unstructured":"Instituto Nacional de Salud - Colombia. Bolet\u00edn No 1 - Observatorio Nacional de Salud Bogot\u00e1: Instituto Nacional de Salud; 2013 http:\/\/www.ins.gov.co\/lineas-de-accion\/ons\/boletin%201\/boletin_web_ONS\/boletin1.html."},{"key":"bibr3-2150132720977733","doi-asserted-by":"publisher","DOI":"10.3109\/13814780309160389"},{"issue":"2","key":"bibr4-2150132720977733","first-page":"205","volume":"30","author":"Machado-Alba JE","year":"2013","journal-title":"Rev Peru Med Exp Salud Publica"},{"issue":"9","key":"bibr5-2150132720977733","first-page":"921","volume":"169","author":"Genest J","year":"2003","journal-title":"CMAJ"},{"key":"bibr6-2150132720977733","doi-asserted-by":"publisher","DOI":"10.21615\/cesmedicina.30.1.1"},{"issue":"3","key":"bibr7-2150132720977733","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1590\/S1020-49892008000300005","volume":"23","author":"Machado JE","year":"2008","journal-title":"Rev Panam Salud Publica"},{"issue":"2","key":"bibr8-2150132720977733","first-page":"67","volume":"8","author":"Restrepo P","year":"2000","journal-title":"Rev Col Cardiol"},{"issue":"6","key":"bibr9-2150132720977733","first-page":"383","volume":"33","author":"Machado-Alba JE","year":"2013","journal-title":"Rev Panam Salud Publica"},{"issue":"3","key":"bibr10-2150132720977733","first-page":"181","volume":"41","author":"Machado-Alba JE","year":"2016","journal-title":"Acta Med Colomb"},{"key":"bibr11-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12053"},{"key":"bibr12-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.06.050"},{"issue":"11","key":"bibr13-2150132720977733","first-page":"CD009753","volume":"11","author":"Jakob T","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"bibr14-2150132720977733","first-page":"202","volume":"21","author":"Mu\u00f1oz OM","year":"2014","journal-title":"Rev Colomb Cardiol"},{"issue":"25","key":"bibr15-2150132720977733","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.97.25.2482","volume":"129","author":"Stone NJ","year":"2014","journal-title":"Circulation"},{"key":"bibr16-2150132720977733","doi-asserted-by":"publisher","DOI":"10.4158\/EP171764.APPGL"},{"key":"bibr17-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.07.021"},{"key":"bibr18-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamainternmed.477"},{"key":"bibr19-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2019.06.006"},{"issue":"8","key":"bibr20-2150132720977733","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2005.12.007","volume":"97","author":"Bottorff MB","year":"2006","journal-title":"Am J Cardiol"},{"key":"bibr21-2150132720977733","doi-asserted-by":"publisher","DOI":"10.2165\/10061630-000000000-00000"},{"key":"bibr22-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-010-6266-4"},{"key":"bibr23-2150132720977733","doi-asserted-by":"publisher","DOI":"10.2165\/11597940-000000000-00000"},{"key":"bibr24-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903376186"},{"key":"bibr25-2150132720977733","author":"Rezende Macedo do Nascimento RC","journal-title":"Br J Clin Pharmacol"},{"key":"bibr26-2150132720977733","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0365"},{"key":"bibr27-2150132720977733","doi-asserted-by":"publisher","DOI":"10.4067\/s0034-98872018001201405"},{"key":"bibr28-2150132720977733","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.076"}],"container-title":["Journal of Primary Care &amp; Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2150132720977733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2150132720977733","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2150132720977733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:22:25Z","timestamp":1777508545000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2150132720977733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":28,"alternative-id":["10.1177\/2150132720977733"],"URL":"https:\/\/doi.org\/10.1177\/2150132720977733","relation":{},"ISSN":["2150-1319","2150-1327"],"issn-type":[{"value":"2150-1319","type":"print"},{"value":"2150-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2150132720977733"}}